Fox E, Lovett-Racke AE, Gormley M, Liu Y, et al. A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Mult Scler 2020 Apr 30:1352458520918375. doi: 10.1177/1352458520918375.
PMID: 32351164